Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1692-1696

  Cheng, Iona ^a   Yu, Mimi C ^b   Koh, Woon Puay ^c   Pike, Malcolm C ^a   Kolonel, Laurence N ^d   Henderson, Brian E ^a   Stram, Daniel O ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; GLUCURONIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CHINESE; ETHNIC GROUP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGAPORE; UNITED STATES;

AGE DISTRIBUTION; AGED; ANDROSTANE-3,17-DIOL; ETHNIC GROUPS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SINGAPORE; TESTOSTERONE; UNITED STATES;

EID: 22244448960     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0864     Document Type: Article

References (29)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4-66.
2. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer incidence in five continents, Vol. VI. IARC Scientific Publications. Lyon, France: International Agency for Research on Cancer; 1992.
3. Stanford J, Stephenson R, Coyle L, et al. Prostate cancer trends 1973-1995. Bethesda, MD: SEER Program National Cancer Institute; 1999.
4. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, Vol. VIII. IARC Scientific Publications. Lyon, France: International Agency for Research on Cancer; 2002.
5. WHO. Globocan 2000: cancer incidence, mortality, and prevalence worldwide, version 1.0, http://www-depdb.iarc.fr/who/menu.htm. Lyon: IARC Press; 2001.
6. Hankin JH, Stram DO, Arakawa K, et al. Singapore Chinese Health Study:development, validation, and calibration of the quantitative food frequency questionnaire. Nutr Cancer 2001;39:187-95.
7. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles:baseline characteristics. Am J Epidemiol 2000;151:346-57.
8. Furuyama S, Mayes DM, Nugent CA. A radioimmunoassay for plasma testosterone. Steroids 1970;16:415-28.
9. Narang R, Rao J, Savjani G, Gentzschien E, Stanczyk FZ. Radioimmunoassay kit for the quantitative measurement of androstanediol glucuronide in unextracted serum. 17th National Meeting of the Clinical Ligand Assay Society; Chicago, Illinois; 1991.
10. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer incidence in five continents, Vol. III. IARC Scientific Publications. Lyon, France: International Agency for Research on Cancer; 1987.
11. Waterhouse J, Muir C, Shanmugaratnam K, Powell J. Cancer incidence in five continents, Vol. IV. IARC Scientific Publications Lyon, France: International Agency for Research on Cancer; 1982.
12. Muir C, Waterhouse J, Mack T, Powell J, Whelan SL. Cancer incidence in five continents, Vol. V. IARC Scientific Publications. Lyon, France: International Agency for Research on Cancer; 1987.
13. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. Cancer incidence in five continents, Vol. VII. IARC Scientific Publications Lyon, France: International Agency for Research on Cancer; 1997.
14. Surveillance E. End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U.S. for Expanded Races/Hispanics (1990-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004. Underlying mortality data provided by NCHS (http:// www.cdc.gov/nchs).
15. Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Sendi, Japan: Tohoku University of Medicine; 1960.
16. Neter J, Wasserman W, Kutner MH. Applied linear statistical methods. Homewood, IL: Richard D. Irwin, Inc.; 1990.
17. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 1999; 162:293-306.
18. Shibata A, Whittemore AS, Imai K, et al. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 1997;89:1716-20.
19. Shimizu H, Ross RK, Bernstein L. Possible underestimation of the incidence rate of prostate cancer in Japan. Jpn J Cancer Res 1991;82:483-5.
20. Ministry of Health. Prostate cancer. Singapore clinical practice guidelines. Singapore; 2003.
21. Schottenfeld D, Colditz GA. Prostate cancer screening practices and cancer control research (United States). Cancer Causes Control 2002;13:1-5.
22. Yian T. Highlights of the 1998 National Health Survey. Singapore: Ministry of Health; 2000.
23. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-7.
24. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86:312-5.
25. Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004;108:418-24.
26. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
27. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002;11:1041-7.
28. Ross RK, Bernstein L, Lobo RA, et al. 5-α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339:887-9.
29. Wu AH, Whittemore AS, Kolonel LN, et al. Lifestyle determinants of 5α-reductase metabolites in older African-American, white, and Asian-American men. Cancer Epidemiol Biomarkers Prev 2001;10:533-8.